1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
60952153342E343DB00258684004C81ED
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/digital-trends-biopharma-launch-strategy-investment
18
19
203.239.192.241
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Digital Technology Digital Marketing Strategies

Digital Trends in Biopharma Launch Strategy and Investment

ID: PSM-375


Features:

8 Info Graphics

20 Data Graphics

310+ Metrics

5 Narratives


Pages: 36


Published: 2021


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
The pandemic created chaos for the launch plans of many biopharma companies, pushing them for the first time to fully integrate complete digital strategies into their traditional launch models.

Best Practices, LLC undertook this benchmarking research to examine the most important trends and accelerated pace of digital adoption to drive innovative biopharma launches. The report identifies high-value emerging digital activities and effective tactics, explores overall digital strategies, spotlights investment trends, and captures key lessons learned from new launches.

Industries Profiled:
Biotech; Pharmaceutical; Consulting; Medical Device; Chemical; Health Care; Biopharmaceutical; Clinical Research; Laboratories; Marketing


Companies Profiled:
Amgen; Bending Brook LLC; Boehringer Ingelheim; Carl Zeiss Meditec; Inc.; Genentech; Kaleidoscope Health Ventures; Merck; Roche; Sanofi; Smith & Nephew; UCB Pharma; West 53rd St Digital

Study Snapshot

Best Practices, LLC engaged 12 leaders from 12 biopharma organizations in this study through a benchmarking survey.

Key topics covered in this report include:

  • Digital Activities and Acceleration
  • Digital Impact on a Successful Launch
  • Investment Trend & Effective Assessment

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Companies have implemented metrics to measure the effectiveness of investment in digital platforms:
    • On average, companies increased their budget allocation for digital launch by 200% during the course of the pandemic.
    • To validate these investments, companies have implemented qualitative and quantitative metrics:
      • Quantitative metrics help in measuring the reach of digital communication to the patients and HCPs.
      • Qualitative metrics assist in understanding HCPs’ feedback.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Research OverviewPg. 4
II.
Universe of LearningPg. 5
III.
Key InsightsPg. 6
IV.
Digital Activities and AccelerationPg. 7
V.
Digital Impact on a Successful LaunchPg. 20
VI.
Investment Trends & Effective AssessmentPg. 27
VII.
Participant DemographicsPg. 33
VIII.
About Best Practices LLCPg. 36

    List of Charts & Exhibits

    I. Digital Activities and Acceleration Supporting New Launches

    • Most valuable new digital activities for product launch
    • Top quantitative metrics for validating digital strategy and investment to senior leadership
    • Top qualitative metrics for validating digital strategy and investment to senior leadership
    • Percentage of total launch budget earmarked for digital programs in 2019 vs. today
    • Digital acceleration in launch - Company A
    • Digital acceleration in launch - Company B
    • Digital acceleration in launch - Company C
    • Digital acceleration in launch - Company D
    • Digital acceleration in launch - Company E
    • Percentage of total digital budget allocated to each of the listed digital operational areas to support the launch product
    • Importance of listed factors in increased allocation of launch resources toward digital
    • Role of new digital approaches in current and future go-to-market strategy

    II. Digital Impact on a Successful Launch

    • Impact of listed digital activities and programs used to support a successful pharma product launch – New product planning and development activities
    • Impact of listed digital activities and programs used to support a successful pharma product launch – Medical and patient support activities
    • Impact of listed digital activities and programs used to support a successful pharma product launch – Marketing activities
    • Impact of listed digital activities and programs used to support a successful pharma product launch – Sales activities
    • Other high-value digital activities or programs for launch
    • Structuring launch team to ensure successful planning, development and execution of critical digital initiatives

    III. Investment Trends & Effective Assessment

    • Change in launch spend across each of the listed critical digital program areas – New product planning and development activities
    • Change in launch spend across each of the listed critical digital program areas – Medical and patient support activities
    • Change in launch spend across each of the listed critical digital program areas – Marketing activities
    • Change in launch spend across each of the listed critical digital program areas – Sales activities
    • Effective metrics for measuring digital performance in launch

    IV. Participant Demographics

    • Participant job title and industry represented
    • Participant geographic responsibility and therapeutic area represented